1. New Approaches for the Management of Diabetes: Practical Considerations for Clinicians

2. SGLT2 Inhibitors in Phase 3 Trials

6. Dapagliflozin†: Reduction in FPG at Week 24 Across Studies

7. Dapagliflozin* 10 mg vs Metformin XR vs Combination Therapy: HbA1c at Week 24

8. Dapagliflozin† 10 mg vs Glipizide as Add-on to Metformin

9. Dapagliflozin†: Change in Body Weight at Week 24

12. Summary: Efficacy of SGLT2 Inhibitors*

13. Elements of Decision-Making for Achieving Glycemic Goals

14. ADA / EASD Position Statement: Managing Hyperglycemia in T2DM

15. Abbreviations

16. Abbreviations (cont)

17. Abbreviations (cont)

18. References

19. References (cont)

20. References (cont)

21. References (cont)

22. References (cont)

23. References (cont)

24. References (cont)

25. References (cont)

26. References (cont)